Got Patients With Refractory axSpA or PsA? Consider This Option

(MedPage Today) — Although most patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) didn’t respond adequately to the interleukin-17 (IL-17) inhibitor ixekizumab (Taltz), enough did that it should still be considered in such…

Source link : https://www.medpagetoday.com/rheumatology/arthritis/116666

Author :

Publish date : 2025-07-25 12:48:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Got Patients With Refractory axSpA or PsA? Consider This Option

Case Reports Describe Itch Relief With Nemolizumab

Hulk Hogan Dead at 71 Following Cardiac Arrest

Related Posts

Which Docs Are Leaving the Workforce in Greater Numbers?

Where Are U.S. Antibiotics Originating? Aldosterone and Heart Disease Risk

Pronatalism and Public Health Are Incompatible

Poor Heart Health in Youth Linked With Later Pregnancy Risks

Report shows ‘stark’ gender gap in HIV prevention across West Midlands

GLP 1s and Libido: An Effect That May Fly Under the Radar

Which Docs Are Leaving the Workforce in Greater Numbers?

Where Are U.S. Antibiotics Originating? Aldosterone and Heart Disease Risk

Pronatalism and Public Health Are Incompatible

Poor Heart Health in Youth Linked With Later Pregnancy Risks

Report shows ‘stark’ gender gap in HIV prevention across West Midlands

GLP 1s and Libido: An Effect That May Fly Under the Radar

Starving Children Screaming for Food as U.S. Aid Cuts Unleash Devastation and Death

Could Oral Microbiome Test Indicate Pancreatic Cancer Risk?

Categories

Archives